What’s the concern? Debt. But not the national debt or even deficits, which are topics themsel...
Bristol-Myers: Setback Creates Opportunity
08/26/2016 8:00 am EST
This featured recommendation is pioneering innovative medicines in the area of immuno-oncology, which unlock the body’s own immune system to battle cancer, explains Todd Shaver, editor of Bullmarket.com.
Bristol-Myers Squibb (BMY) introduced its first immuno-oncology agent in 2011; Yervoy treats metastatic melanoma (also known as skin cancer).
However, Bristol-Myers recently announced that one of its more promising up and coming drugs being pioneered for the area of immuno-oncology surprisingly did not pass trial.
Specifically the monotherapy frontline lung phase III study failed (a lung cancer drug).
This was a significant setback for Bristol-Myers, delaying the company’s move into the largest segment of the immune-oncology end market.
The failed trial was a tough pill to swallow for investors and caused Bristol-Myers shares to sell off over 25%, erasing more than $25 billion of market capitalization.
However, the game is far from over. The end market for immune-oncology is quickly evolving. There is broad consensus that by 2018 the end market will expand into a combo market that works with multiple drugs, some of which Bristol-Myers is hard at work developing.
To the extent these other drug studies for Bristol-Myers have success, the company is expected to regain its leadership position in the immune-oncology market.
After all the recent EPS revisions and noise, the consensus EPS outlook still calls for a 2016-2018 compound annual growth rate of 15%, a very healthy pace reflective of a still resilient large cap blue chip business model.
The balance sheet is very strong and the current yield of 2.5% is a nice extra benefit while we wait and is very safe, representing only half of current EPS.
The sell-off is setting up an opportunistic entry point. BMY appears to be a solid investment opportunity for those with the patience to hold for a 12-18-month time period.
By Todd Shaver, Editor of Bullmarket.com
Related Articles on STOCKS
The bulls are still long from both buy signals, signals are likely to fail. Most bulls will exit thi...
Macquarie Infrastructure Company (MIC) dropped over 40% after it reported fourth-quarter earnings on...
A trio of semiconductor stocks — NVIDIA (NVDA), Qorvo (QRVO), and Skyworks (SWKS) — earn...